Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 8.14 SEK 7.81%
Market Cap: 389.7m SEK

Moberg Pharma AB (publ)
Investor Relations

Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.

Show more
Loading

Earnings Calls

2025 Q1
Apr 29, 2025
Show Transcript
Previous
Next
Alfa Laval reports stable demand, improving margins, and upcoming growth
2025 Q1
Apr 29, 2025

In Q1, Alfa Laval experienced stable demand across divisions, with order intake down 3% organically. Invoicing rose by 10%, boosting margins to 17.7%. The Energy division expects stronger demand in Q2, while Food & Water remains stable. Notably, the Marine division anticipates diminished cargo pumping demand but boasts a robust order book of SEK 52 billion. The company emphasized its debt-free status and forecasted a SEK 8.5 dividend per share. Alfa Laval's acquisition of Fives Cryogenics aims for SEK 2-2.5 billion in revenue, enhancing growth prospects in LNG and carbon capture technologies, crucial for future expansion.

Show Full Analysis

Management

Ms. Anna Ljung BA, M.Sc.
Chief Executive Officer
No Bio Available
Ms. Marie Moberg
Co-Founder
No Bio Available
Mr. Mark Beveridge
Vice President of Finance
No Bio Available
Dr. Christina Erixon
Head of Pharmaceutical Development & Operations
No Bio Available
Dr. Amir Tavakkol Ph.D.
Chief Scientific Officer
No Bio Available
Gunilla Wengström
Senior Director of Sales & Marketing
No Bio Available
Anders Broijersen M.D., Ph.D.
Chief Medical Officer
No Bio Available
Mr. Robert Ehrl
Head of Supply
No Bio Available

Contacts

Address
STOCKHOLM
Bromma
Gustavslundsvagen 42, 5 tr.
Contacts